Combined ALCAM and PSA serum levels were available for 196 patients with survival outcomes (alive, n = 183; died of PRCa, n = 13) and 51 patient with M scores (M0, n = 45; M1, n = 6). This evidence concerns the gene KLK3 and pure red-cell aplasia.